MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France,…
MaaT PharmaJuly 13, 2023
MaaT Pharma Announces New Appointments to the Board and Executive Team Appointments to the Board…
MaaT PharmaJune 21, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaJune 9, 2023
MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory…
MaaT PharmaMay 26, 2023
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023 As of March…
MaaT PharmaMay 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaMay 3, 2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for…
MaaT PharmaApril 24, 2023
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting…
MaaT PharmaApril 11, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaApril 4, 2023
